BridgeBio Pharma BBIO Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's stock-based comp?
- BridgeBio Pharma (BBIO) reported stock-based comp of $33.24M in Q1 2026.
- How has BridgeBio Pharma's stock-based comp changed year-over-year?
- BridgeBio Pharma's stock-based comp increased by 28.4% year-over-year, from $25.88M to $33.24M.
- What is the long-term trend for BridgeBio Pharma's stock-based comp?
- Over 4 years (2021 to 2025), BridgeBio Pharma's stock-based comp has grown at a 7.5% compound annual growth rate (CAGR), from $99.51M to $133.02M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock.
- How do you interpret stock-based comp?
- Higher levels indicate significant dilution to shareholders, while lower levels suggest more conservative equity compensation practices.
- How does stock-based comp compare across companies?
- Common in high-growth biotech and tech sectors as a tool for talent retention.